title: Necrotizing fasciitis in myelodysplastic syndrome: an exceptionally rare occurrence.
authors.forename: Pasquale
authors.initials: P
authors.lastname: Niscola
authors.forename: Andrea
authors.initials: A
authors.lastname: Tendas
authors.forename: Luca
authors.initials: L
authors.lastname: Cupelli
authors.forename: Benedetta
authors.initials: B
authors.lastname: Neri
authors.forename: Laura
authors.initials: L
authors.lastname: Scaramucci
authors.forename: Luciana
authors.initials: L
authors.lastname: Morino
authors.forename: Marco
authors.initials: M
authors.lastname: Giovannini
authors.forename: Stefano
authors.initials: S
authors.lastname: Fratoni
authors.forename: Paolo
authors.initials: P
authors.lastname: de Fabritiis
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use*; D018890:Chemoprevention; D019115:Fasciitis, Necrotizing / Q000175:diagnosis / Q000209:etiology* / Q000382:microbiology; D017809:Fatal Outcome; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000628:therapy; D012074:Remission Induction / Q000379:methods; D012307:Risk Factors; D033581:Stem Cell Transplantation
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine